FDA Panel Leans Toward Including CYP2D6 Dx in Tamoxifen Label, But is Split on Language | GenomeWeb
A majority of an FDA advisory panel believes the agency should update the label for the breast cancer drug tamoxifen to include information about CYP2D6 genotype testing, but the panelists have not reached a consensus on certain details of the issue.
Specifically, the FDA’s Pharmaceutical Science Clinical Pharmacology Subcommittee, which met Oct. 18, was split over whether the label should “recommend” the genetic test or make it an “option” for health care providers and patients to discuss.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.